Skip to main content
SpringerLink
Log in

Peptide Receptor Radionuclide Therapy

  • Chapter
Clinical Nuclear Medicine

  • 2569 Accesses

Abstract

This chapter is based on an earlier article with the same title and by the same authors which appeared in Best Practice & Research: Clinical Gastroenterology, August 2005

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Andersson P, et al. (1996) Internalization of indium-Ill into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phel-octreotide. J Nucl Med 37(12): 2002–2006

    PubMed  CAS  Google Scholar 

  • Anthony LB, et al. (2002) Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 32(2):123–132

    Article  PubMed  Google Scholar 

  • Bakker WH, et al. (1991) In vivo application of [111 In-DTPA-D-Phel]-octreotide for detection of somatostatin receptorpositive tumors in rats. Life Sci 49(22):1593–1601

    Article  PubMed  CAS  Google Scholar 

  • Barone R, et al. (2004) Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues. Nephrol Dial Transplant 19(9):2275–2281

    Article  PubMed  CAS  Google Scholar 

  • Barone R, et al. (2005) Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: Relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 46(1 Suppl):99–106

    Google Scholar 

  • Baum RP, et al. (2004a) Intravenous and intra-arterial peptide receptor radionuclide therapy (PRRT) using Y-90-DOTA-Tyr3-octreotate (Y-90-DOTA-TATE) in patients with metastatic neuroendocrine tumors. Eur J Nucl Med 31(Suppl 2):S238 (abstract)

    Google Scholar 

  • Baum RP, et al. (2004b) Peptidrezeptorvermittelte Radiotherapie (PRRT) neuroendokrinertumoren klinischen Indikationen und Erfahrung mit 90Yttrium-markierten Somatostatinanaloga. Der Onkologe 10(10):1098–1110

    Article  Google Scholar 

  • Béhé M, et al. (2003) Upregulation of gastrin and somatostatin receptor after irradiation. Eur J Nucl Med 44(Suppl2):S218 (abstract)

    Google Scholar 

  • Bodei L, et al. (2003) Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: A phase I study. Eur J Nucl Med Mol Imaging 30(2): 207–216

    Article  PubMed  CAS  Google Scholar 

  • Bodei L, et al. (2004) Receptor radionuclide therapy with (90) Y-[DOTA](0)-Tyr(3)-octreotide ((90)Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 31(7): 1038–1046

    Article  PubMed  CAS  Google Scholar 

  • Bruno JF, Berelowitz M (1993) Somatostatin receptors: Orphan that found family and function. Mol Cell Neurosci 4(4): 307–309

    Article  CAS  PubMed  Google Scholar 

  • Buscombe JR, et al. (2003) Long-term efficacy of high-activity 111 In-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 44(1):1–6

    PubMed  CAS  Google Scholar 

  • Bushneil D, et al. (2003a) Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastases. Cancer Biother Radiopharm 18(4):581–588

    Article  CAS  Google Scholar 

  • Bushneil D, et al. (2003b) Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. J Nucl Med 44(10):1556–1560

    Google Scholar 

  • Capello A, et al. (2003) Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide. J Nucl Med 44(1): 98–104

    PubMed  CAS  Google Scholar 

  • Chinol M, et al. (2002) Receptor-mediated radiotherapy with Y-DOTA-D-Phe-Tyr-octreotide: The experience of the European Institute of Oncology group. Semin Nucl Med 32(2): 141–147

    Article  PubMed  Google Scholar 

  • Cybulla M, et al. (2001) End-stage renal disease after treatment with 90Y-DOTATOC. Eur J Nucl Med 28(10):1552–1554

    Article  PubMed  CAS  Google Scholar 

  • de Jong M, et al. (1996) Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 37(8):1388–1392

    PubMed  Google Scholar 

  • de Jong M, et al. (1998) Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 58(3):437–441

    PubMed  Google Scholar 

  • de Jong M, et al. (2001a) Tumor response after [(90)Y-DO-TA(0), Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 42(12):1841–1846

    PubMed  Google Scholar 

  • de Jong M, et al. (2001b) Receptor-targeted radionuclide therapy using radiolabelled somatostatin analogues: Tumour size versus curability. J Nucl Med 28(8):1026 (abstract)

    Google Scholar 

  • de Jong M, et al. (2002) Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings. Semin Nucl Med 32(2):133–140

    Article  PubMed  Google Scholar 

  • de Jong M, et al. (2003) Radiolabelled peptides for tumour therapy: Current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging 30(3):463–469

    Article  PubMed  CAS  Google Scholar 

  • de Jong M, et al. (2005) Combination radionuclide therapy using 177Lu-and 90Y-labeled somatostatin analogs. J Nucl Med 46(1 Suppl):13–17

    Google Scholar 

  • Emami B, et al. (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21(l):109–122

    PubMed  CAS  Google Scholar 

  • Hofland LJ, et al. (1995) Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: Increase by unlabeled octreotide. Endocrinology 136(9):3698–3706

    Article  PubMed  CAS  Google Scholar 

  • Hofland LJ, et al. (2003) Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111 In-DTPA-D-Phel]octreotide in somatostatin receptor-positive organs. J Nucl Med 44(8):1315–1321

    PubMed  CAS  Google Scholar 

  • Jamar F, et al. (2003) 86Y-DOTA(0)-D-Phel-Tyr3-octreotide (SMT487)–a phase 1 clinical study: Pharmacokinetics, bio-distribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 30(4):510–518

    Article  PubMed  CAS  Google Scholar 

  • John M, et al. (1996) Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut 38(l):33–39

    Article  PubMed  CAS  Google Scholar 

  • Krenning EP, et al. (1992) Somatostatin receptor scintigraphy with indium-111-DTPA-d-phe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 33(5):652–658

    PubMed  CAS  Google Scholar 

  • Krenning EP, et al. (1993) Somatostatin receptor scintigraphy with [111 In-DTPA-D-Phel]-and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20(8):716–731

    Article  PubMed  CAS  Google Scholar 

  • Krenning EP, et al. (1994) Radiotherapy with a radiolabeled somatostatin analogue, [111in-DTPA-D-Phel]-octreotide. A case history. Ann N Y Acad Sci 733:496–506

    Article  PubMed  CAS  Google Scholar 

  • Krenning EP, et al. (1999) Radiolabelled somatostatin analogues) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 10(Suppl 2):S23–S29

    Article  PubMed  Google Scholar 

  • Kwekkeboom D, et al. (2000) Peptide receptor imaging and therapy. J Nucl Med 41(10):1704–1713

    PubMed  CAS  Google Scholar 

  • Kwekkeboom DJ, et al. (2001) [177Lu-DOTA0, Tyr3]octreotate: Comparison with [11 Hn-DTPA0]octreotide in patients. Eur J Nucl Med 28(9):1319–1325

    Article  PubMed  CAS  Google Scholar 

  • Kwekkeboom DJ, et al. (2003a) Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0), Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging 30(3):417–422

    Article  PubMed  CAS  Google Scholar 

  • Kwekkeboom DJ, et al. (2003b) Treatment with Lu-177-DOTA-Tyr3-octreotate in patients with neuroendocrine tumors: Interim results. Eur J Nucl Med Mol Imaging 30(Suppl 2) (Suppl 2):S231 (abstract)

    Google Scholar 

  • Kwekkeboom DJ, et al. (2005) Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23(12): 2754–2762

    Article  PubMed  CAS  Google Scholar 

  • McCarthy KE, et al. (2000) In situ radiotherapy with 111Inpentetreotide. State of the art and perspectives. Q J Nucl Med 44(l):88–95

    PubMed  CAS  Google Scholar 

  • Moll S, et al. (2001) A new cause of renal thrombotic microangiopathy: Yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis 37(4):847–851

    Article  PubMed  CAS  Google Scholar 

  • O’Donoghue JA, et al. (1995) Relationships between tumor size and curability for uniformly targeted therapy with betaemitting radionuclides. J Nucl Med 36(10):1902–1909

    PubMed  CAS  Google Scholar 

  • Otte A, et al. (1998) Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351(9100):417–418

    Article  PubMed  CAS  Google Scholar 

  • Otte A, et al. (1999) Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med 26(11):1439–1447

    Article  PubMed  CAS  Google Scholar 

  • Paganelli G, et al. (2001) Receptor-mediated radiotherapy with 90Y-DOTA-D Phel-Tyr3-octreotide. Eur J Nucl Med 28(4): 426–434

    Article  PubMed  CAS  Google Scholar 

  • Paganelli G, et al. (2002) 90Y-DOTA-D-Phel-Tyr3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 66(6):393–398

    Article  PubMed  CAS  Google Scholar 

  • Panetta R, et al. (1994) Molecular cloning, functional characterization, and chromosomal localization of a human somatostatin receptor (somatostatin receptor type 5) with preferential affinity for somatostatin-28. Mol Pharmacol 45(3):417–427

    PubMed  CAS  Google Scholar 

  • Reubi JC, Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: Molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30(5):781–793

    Article  PubMed  CAS  Google Scholar 

  • Reubi JC, et al. (1990) Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: Relationship to EGF receptors. Int J Cancer 46(3):416–420

    Article  PubMed  CAS  Google Scholar 

  • Reubi JC, et al. (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27(3):273–282

    Article  PubMed  CAS  Google Scholar 

  • Reubi JC, et al. (2005) Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 46Suppl 1:67S–75S

    PubMed  CAS  Google Scholar 

  • Rohrer L, et al. (1993) Cloning and characterization of a fourth human somatostatin receptor. Proc Natl Acad Sci U S A 90(9):4196–4200

    Article  PubMed  CAS  Google Scholar 

  • Rolleman EJ, et al. (2003) Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 30(l):9–15

    Article  PubMed  CAS  Google Scholar 

  • Sanders C, et al. (1998) Reporting on quality of life in randomised controlled trials: Bibliographic study. BMJ (Clinical Research ed.) 317(7167): 1191–1194

    Google Scholar 

  • Slooter GD, et al. (1999) Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver. Int J Cancer 81(5):767–771

    Article  PubMed  CAS  Google Scholar 

  • Smith MC, et al. (2000) OctreoTher: Ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy. Digestion 62(Suppl l):69–72

    Article  PubMed  CAS  Google Scholar 

  • Stoffel MP, et al. (2001) Radiation nephropathy after radiotherapy in metastatic medullary thyroid carcinoma. Nephrol Dial Transplant 16(5):1082–1083

    Article  PubMed  CAS  Google Scholar 

  • Teunissen JJ, et al. (2004) Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate. J Clin Oncol 22(13):2724–2729

    Article  PubMed  CAS  Google Scholar 

  • Toth-Fejel S, Pommier RF (2004) Relationships among delay of diagnosis, extent of disease, and survival in patients with abdominal carcinoid tumors. Am J Surg 187(5):575–579

    Article  PubMed  Google Scholar 

  • Valkema R, et al. (2002a) Phase I study of peptide receptor radionuclide therapy with [In-DTPA] octreotide: The Rotterdam experience. Semin Nucl Med 32(2):110–122

    Article  PubMed  Google Scholar 

  • Valkema R, et al. (2002b) Phase 1 study of therapy with 90YSMT487 (OctreoTher) in patients with somatostatin receptor (SS-R) positive tumors. J Nucl Med 43 (Suppl):33P (abstract)

    Google Scholar 

  • Valkema R, et al. (2003a) Long-term follow-up of a phase 1 study of peptide receptor radionuclide therapy (PRRT) with (90Y-DOTA0, Tyr3)octreotide in patients with somatostatin receptor positive tumours. Eur J Nucl Med 30(Suppl 2):S232 (abstract)

    Google Scholar 

  • Valkema R, et al. (2003b) Survival in patients with neuroendocrine tumors after treatment with [90Y-DOTA, Tyr) in a phase-1 study. J Nucl Med 44(Suppl 2):136P

    Google Scholar 

  • Valkema R, et al. (2005) Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0, Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate. J Nucl Med 46(1 Suppl):83–91

    Google Scholar 

  • Van Eijck CH (2005) Treatment of advanced endocrine gastroenteropancreatic tumours using radiolabelled somatostatin analogues. Br J Surg 92(11):1333–1334

    Article  PubMed  CAS  Google Scholar 

  • van Putten JWG, et al. (2003) A phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin Cancer Res 9(7):2472–2477

    PubMed  Google Scholar 

  • Virgolini I, et al. (2002) In-and Y-DOTA-lanreotide: Results and implications of the Mauritius trial. Semin Nucl Med 32(2):148–155

    Article  PubMed  Google Scholar 

  • Waldherr C, et al. (2001) The clinical value of [90Y-DOTA]-d-phel-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study. Ann Oncol 12(7):941–945

    Article  PubMed  CAS  Google Scholar 

  • Waldherr C, et al. (2002a) Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 43(5):610–616

    PubMed  CAS  Google Scholar 

  • Waldherr C, et al. (2002b) Does tumor response depend on the number of treatment sessions at constant injected dose using 90yttrium-DOTATOC in neuroendocrine tumors? Eur J Nucl Med 29:S100 (abstract)

    Google Scholar 

  • Wild D, et al. (2003) DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 30(10): 1338–1347

    Article  PubMed  CAS  Google Scholar 

  • Yamada Y, et al. (1992) Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci U S A 89(1):251–255

    Article  PubMed  CAS  Google Scholar 

  • Yamada Y, et al. (1993) Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. Biochem Biophys Res Commun 195(2):844–852

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Erasmus Medical Center, ’s-Gravendijkwal 230, 3015 GD, Rotterdam, The Netherlands

    J. J. M. Teunissen MD, D. J. Kwekkeboom MD, PhD, M. de Jong PhD, J. -P. Esser MD, R. Valkema MD, PhD & E. P. Krenning MD, PhD

Authors
  1. J. J. M. Teunissen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. J. Kwekkeboom MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. de Jong PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. -P. Esser MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Valkema MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. P. Krenning MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Nuclear Medicine, University Hospital Bonn, Sigmund-Freud-Straße 15, D-53127, Bonn, Germany

    Hans-Jürgen Biersack M.D. (Professor and Chairman) (Professor and Chairman)

  2. Nuclear Medicine and Radiology, Albert Einstein College of Medicine Director, Dept. of Nuclear Medicine Montefiore Medical Centre/Moses Division, 111 East 210th Street, Bronx, NY, 10467, USA

    Leonard M. Freeman M.D. (Professor) (Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Teunissen, J.J.M., Kwekkeboom, D.J., de Jong, M., Esser, J.P., Valkema, R., Krenning, E.P. (2007). Peptide Receptor Radionuclide Therapy. In: Biersack, HJ., Freeman, L.M. (eds) Clinical Nuclear Medicine. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-28026-2_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-28026-2_24

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-28025-5

  • Online ISBN: 978-3-540-28026-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation